- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01420354
Can a Spot Urine Replace or Improve 24 Hour Urine Collections in Kidney Stone Patients
Study Overview
Status
Conditions
Detailed Description
BACKGROUND Urinary stone disease is a common problem, causing significant morbidity and sometimes mortality. Stone disease affects 5-10% of the population during their lifetime and of these patients between 30-50% will have at least one recurrent episode.
Urinary stones arise due to crystallization and aggregation of supersaturated ion complexes in the urine. Depending on the concentration of various urinary constituents and the physicochemical characteristics of a given individual's urine (such as pH, volume, calcium citrate concentration etc.), different crystals may precipitate. Therefore therapy is tailored to the individual, based on stone composition and the results of the 24-hour urine collection. The majority of the stones are calcium based (calcium oxalate, calcium phosphate) while the remaining are comprised of uric acid, struvite, cystine or other substances.
While some stones can pass spontaneously, the majority will require some form of treatment, and more than 50% will require surgical intervention. Until the 1980s, treatment of upper urinary tract stones often involved extensive open surgical procedures5. With the introduction of extracorporeal shock-wave lithotripsy (ESWL) and refinements in endourological procedures like percutaneous nephrolithotomy (PCNL), ureteroscopy (URS) techniques, it has now become possible to treat stones in almost all cases without open surgery. Stone management can be divided into three treatment phases. The first phase involves treatment of acute pain and the drainage of an obstructed and possibly infected kidney. The second phase aims to either remove or disintegrate the stone. The third phase is directed towards the prophylaxis of stone recurrence .
The third phase involves the metabolic evaluation of the patient to identify possible risk factors for forming recurrent stones, which consists of a 24 hour urine analysis to determine the content of urinary components such as calcium or oxalate that play a major role in stone disease. High levels of oxalate and calcium contribute to kidney stones recurrences and therapy to reduce these two substances in the urine can reduce recurrence rates. Low levels of citrate also increase the risk for forming stones, and can be treated with alkali such as potassium citrate.
Collecting 24-hour urines for evaluation and therapy can be cumbersome for patients and often leads to incorrect collection, which may be detectable by measuring the amount of creatinine in each sample. Previous attempts to evaluate spot versus 24-hour urines have been made, but more studies are necessary to determine how they compare to the conventional 24-hour collection. A more convenient method for collecting urine samples will facilitate the treatment and future prevention of recurrent kidney stone disease.
The aim of this project is to determine whether spot urines collected separately at key times throughout the day are comparable to the conventional pooled 24-hour urine collection, and whether the former yield more accurate information in terms of the levels of urinary components. Perhaps a patient with normal values for a pooled 24-hour collection may show spikes in certain variables throughout the day that would not be discovered in the 24-hour sample. Furthermore, reducing the collection to a single time point would improve patient compliance making it easier to do subsequent follow-up collections.
HYPOTHESIS AND OBJECTIVES We hypothesize that spot urines can provide equivalent information to that provided by a 24-hour urine test. An added benefit would be if spot urines provide more information for the identification of risk factors in patients who have normal 24-hour urine tests. A third possibility is that our hypothesis is incorrect and that a 24-hour urine sample will provide the most useful data in formulating a stone prevention therapy for our patients.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital, DHCC, Level 6, 2775 Laurel Street
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who have been diagnosed as having calcium based urinary stones
- at least 19 years of age
- do not have any additional serious disease
Exclusion Criteria:
- Patients who do not have calcium based urinary stones (such as: uric acid, cystine, struvite)
- less than 19 years of age
- have a serious alternate disease
- Pregnancy
- Positive Urine Culture
- Active cancer
- Recurrent urinary infections
- Gross hematuria
- Receiving treatment with thiazides (or alternatively can be enrolled if the patient is willing to stop treatment for 2 weeks prior to study)
- Inability to provide informed consent
- Investigator's refusal to include
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Calcium supersaturation and the risk of Calcium Oxalate crystallization will be compared between individual spot urines and conventional 24-hour urine sample
Time Frame: 24 hours divided into 4 time frames (spot urines)
|
24 hours divided into 4 time frames (spot urines)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Identified risk factors for kidney stone patients will be compared between individual spot urines and conventional 24-hour urine sample: volume, pH, Urinary calcium, magnesium, oxalate, citrate, creatinine
Time Frame: 24 hours divided in 4 time frames (spot urines)
|
24 hours divided in 4 time frames (spot urines)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ryan Paterson, University of British Columbia
- Study Director: Roger Sutton, University of British Columbia
- Study Director: Morris Pudek, University of British Columbia
- Study Director: Dirk Lange, University of British Columbia
- Study Director: Meredith Cushing, Vancouver General Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H08-02934
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Stones
-
Indiana Kidney Stone InstituteUniversity of Washington; VA Puget Sound Health Care SystemCompleted
-
Omeros CorporationCompletedUrinary Calculi | Renal Calculi | Kidney Stones | Urinary Stones | Urinary Tract StonesUnited States
-
Mayo ClinicCompletedKidney Calculi | Nephrolithiasis | Kidney Stones | Renal StonesUnited States, Canada
-
United States Naval Medical Center, San DiegoUnknown
-
University of British ColumbiaPercutaneous Systems, Inc.Completed
-
Robert SworWilliam Beaumont HospitalsCompletedKidney Stones | Ureteral StonesUnited States
-
Mansoura UniversityUnknownUrologic Diseases | Stones, Kidney | Stone, Urinary | Shock Wave LithotripsyEgypt
-
Mansoura UniversityRecruitingUrinary Stones | Renal StoneEgypt
-
Services Hospital, LahoreCompleted
-
Adva-TecUniversity of British ColumbiaCompletedUnilateral Ureteral Stone | Renal Stone Fragments ≤ 2mmCanada